Bioreactors Market Analysis & Forecast: 2026-2033
The bioreactors market size is anticipated to grow at a CAGR of 19.2% with USD 18.5 Bn in 2026 and is expected to reach USD 34.2 Bn in 2033. The growth is driven by the rising biologics, vaccine, and cell/gene therapy manufacturing, with FDA reporting 46 novel drug approvals in 2025 and maintaining an approved list of licensed cellular and gene therapy products, supporting demand for scalable bioprocessing systems.
The surge in the incorporation of Single-Use Technologies (SUT), particularly Single-Use Bioreactors (SUBs), is substantially transforming the U.S. bioreactor industry. The manufacturers are shifting from traditional stainless-steel systems toward flexible, disposable plastic assemblies to support faster, more cost-effective production of biologics (accounts for nearly half of US prescription drug spending), biosimilars, as well as personalized medicines. This transition is mainly owing to the need for speed, flexibility, and operational efficiency.
The growing demand for biologics like monoclonal antibodies, vaccines, and advanced cell and gene therapies, is one of the key factors that contributes to the increased adoption of single-use bioreactors. These systems deliver quicker turnaround time and they also allow flexible changeovers between batches. As a result, they are particularly well-suited for multi-product facilities and Contract Manufacturing Organizations (CMOs).
The single-use bioreactors also help in reducing capital expenditure by lowering the need for large-scale facility construction, cleaning-in-place systems, and steam-in-place infrastructure. The disposable assemblies also minimize the risk of cross-contamination between production runs. This improves both manufacturing safety as well as process reliability.
One of the major breakthrough in bioreactor technology is the integration of real-time, AI-driven monitoring systems along with automated control systems. It is shifting bioprocessing from fixed, reactive methods toward a more dynamic, adaptive, and autonomous operations. With the use of machine learning, IoT-enabled sensors, and digital twins, these systems help optimize microbial and mammalian cell culture conditions, thus leading to better yield, improved consistency, along with shorter production timelines.
The modern bioreactors are equipped with in-line sensors like NIR spectroscopy, dielectric spectroscopy, and advanced flow cytometry. These tools provide real-time data on key parameters like cell density, metabolite concentration, pH, and dissolved oxygen levels. AI models such as deep learning and reinforcement learning systems analyze this data continually to predict process deviations before they occur.
This closed-loop control allows automatic adjustments in feeding rates, stirring speed, and oxygen transfer. As a result, the manufacturers can improve process efficiency as well as support more reliable biomanufacturing outcomes.
For instance, in February 2026, Nucleus Biologics launched Krakatoa K500 in San Diego, CA. It is a pod-based, closed single-use media and buffer manufacturing system designed for bioreactor-scale operations. The system includes integrated analytics, QR-code-driven execution, and automated digital batch records, thereby helping support GMP-compliant manufacturing.
|
Current Event |
Description and its Impact |
|
FDA PreCheck Pilot Program for Domestic Pharmaceutical Manufacturing |
|
|
FDA Advanced Manufacturing Technologies Designation Program |
|
|
EU Biotechnology and Biomanufacturing Policy Push |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Steel bioreactor is projected to account for the largest bioreactors market share of 46.80% in 2026. The leadership is mainly attributed to the strong demand for large-scale, high-volume biopharmaceutical production, where durability, sterility, process control, and long operational life are critical. At present, the stainless steel bioreactors account for around 92% of installed capacity. While bioreactors with capacities of more than 10,000 liters constitute to nearly 55% of total installed capacity. This highlights the segment’s continued importance in commercial-scale manufacturing.
The stainless steel systems support stringent cleaning and sterilization protocols, including Clean-in-Place (CIP) and Steam-in-Place (SIP), thereby making them highly suitable for the production of monoclonal antibodies, vaccines, recombinant proteins, and other biologics. In addition, the leading pharmaceutical manufacturers are continually investing in large-scale biologics facilities in order to meet the rising global demand.
The steel bioreactors offer superior scalability, batch-to-batch consistency, and lower long-term cost per batch, thereby sustaining their dominance in established production environments despite the growing adoption of single-use bioreactor systems.
To learn more about this report, Request Free Sample
Based on usage, full scale production is poised to dominate the market and accounts for a considerable 59.8% share in 2026. This is because the manufacturers are shifting from pilot-scale batches to commercial-volume biologics production. The rising demand for blockbuster biologics, biosimilars, vaccines, and cell and gene therapies is prompting the business to invest in larger and more reliable production infrastructure.
One of the key factors contributing to this growth is massive capacity expansion. The leading biomanufacturers are adding large-scale cell culture facilities equipped with high-capacity stainless-steel bioreactors like 20,000-liter systems to support commercial manufacturing volumes. In parallel, contract drug manufacturing organizations (CDOs) are growing in importance in the world's drug production. This is because drug companies are outsourcing production to partners who can provide scale, cost-effectiveness, as well as consistent quality.
The segment is gaining advantages from recent advancements in single-use bioreactor technology. The larger single-use systems, now reaching around 5,000–6,000 liters, allow manufacturers to achieve full-scale production while reducing cleaning time, contamination risk, and changeover complexity. Moreover, as more advanced therapies move from clinical development to approved commercial use, manufacturers are replacing research-grade and pilot systems with validated, GMP-compliant full-scale bioreactors to ensure consistent supply.
To learn more about this report, Request Free Sample
North America is set to account for the leading position in the Bioreactors Market. The region occupies a substantial 38.40% share in 2026. The growth is mainly driven by strong biologics manufacturing capacity, rising demand for monoclonal antibodies, vaccines, biosimilars, and cell and gene therapies across the U.S. and Canada. The U.S. is still a major biopharmaceutical production hub. This is largely attributed to FDA approvals and large-scale investments in commercial biologics facilities. In 2025, the FDA CDER approved 46 novel drugs, which included new biologic products, thereby strengthening the need for cutting edge bioreactor systems.
The region’s growth is also backed by major capacity expansions and product innovation. For example, in September 2025, Fujifilm Biotechnologies opened its Holly Springs, North Carolina site with 8 × 20,000 L mammalian cell culture bioreactors. The second phase is planned to double this to about 16 bioreactors. In addition, in April 2025, Culture Biosciences, a leader in online biomanufacturing, launched Stratyx™ 250, the first mobile, cloud-connected bioreactor. This system offers biotech companies greater ease, automation, and remote process control, thereby allowing for more effective and large-scale biomanufacturing solutions. These developments are expected to continue driving bioreactors market growth in North America.
The Asia Pacific region is poised to be as the fastest-growing region through 2026-2033. The region’s growth is owing to the rising biologics production, expanding biosimilar pipelines, vaccine manufacturing, and increasing CDMO investments across China, India, South Korea, Japan, and Singapore. Countries such as India and China are strengthening domestic biopharmaceutical manufacturing, while Singapore and South Korea are becoming preferred hubs for advanced biologics and contract pharmaceutical manufacturing. The CDSCO in India also released revised guidelines for similar biologics in 2025, thus propelling stronger biosimilar development and regulatory confidence.
Besides this, the region is witnessing major biomanufacturing spending. For instance, in May 2024, AstraZeneca had made an announcement of USD 1.5 billion ADC manufacturing plant in Singapore. This is the firm's first full-scale antibody-drug conjugate production site. In addition, India is also putting greater efforts on becoming a global biopharma center. This is supported by government plans to expand biologics and biomanufacturing abilities.
In addition, in April 2025, Thermo Fisher Scientific Inc., one of the global leader in serving science, announced the launch of the 5L DynaDrive Single-Use Bioreactor (S.U.B.). It is designed to address the evolving needs of modern bioprocessing. The 5L DynaDrive expands the company's extensive bioreactor portfolio, providing seamless scalability from 1 to 5,000 liters. It accelerates bench-scale process development while enabling a cost-effective transition from bench to commercialization with consistent reactor design and film across all scales.
These developments are expected to increase demand for single-use, stainless-steel, pilot-scale, and commercial-scale bioreactors across the region.
The United States Bioreactors Market is witnessing robust activity mainly driven by rising biologics production, CDMO expansion, and growing demand for scalable cell-culture manufacturing. The market is characterized by a shift toward large-volume stainless-steel systems and flexible single-use bioreactors for monoclonal antibodies, vaccines, biosimilars, and cell and gene therapies.
In March 2025, Cytiva upgraded its Xcellerex X-platform portfolio in order to meet the growing demands with the addition of 500L and 2,000L bioreactors. The X-platform is a versatile and dependable single-use system designed to boost operational efficiency as well as production capacity, all while reducing costs, minimizing risks, and speeding up the journey of life-changing therapeutics to the next clinical milestone.
Overall, the rising biologics approvals, CDMO investments, as well as domestic manufacturing resilience are speeding up bioreactor adoption in the U.S. biopharmaceutical industry.
The China Bioreactors Market is poised for steady growth over the forthcoming years. The growth is owing to rapid expansion of biologics, biosimilars, vaccines, cell therapies, and domestic biopharmaceutical manufacturing capacity. China’s biomanufacturing industry reached around RMB 1.1 trillion (USD 157.3 billion) in 2025, reflecting strong government support, rising biotech innovation, and increasing demand for scalable production platforms.
In addition to this, large-scale single-use bioreactor adoption is increasing as Chinese CDMOs and biopharma companies focus on faster batch changeovers, lower contamination risk, and flexible scale-up from clinical to commercial production. In June 2024, WuXi Biologics installed three 5,000 L single-use bioreactors at its MFG20 facility in Hangzhou. This strengthened its drug substance manufacturing capacity for large-scale biologics production.
Overall, rising biologics pipelines, biosimilar commercialization, and local biomanufacturing investment are strengthening bioreactor demand in China.
Some of the major key players in Bioreactors Industry are Thermo Fisher Scientific, Inc., Merck KGaA, GE Healthcare, Pall Corporation, ZETA Holdings GmbH, Sartorius AG BBI, Solaris, Praj HiPurity Systems Limited, BiOENGiNEERiNG, INC., Infors AG, and Appplikon Biotechnology, Inc.
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 18.5 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 19.2% | 2033 Value Projection: | USD 34.2 Bn |
| Geographies covered: |
|
||
| Segments covered: |
|
||
| Companies covered: |
Thermo Fisher Scientific, Inc., Merck KGaA, GE Healthcare, Pall Corporation, ZETA Holdings GmbH, Sartorius AG BBI, Solaris, Praj HiPurity Systems Limited, BiOENGiNEERiNG, INC., Infors AG, and Appplikon Biotechnology, Inc. |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients
